Bergamo, Italy : 15 - 17 May 2019
This EACR-ESMO Joint Conference will provide a comprehensive overview of liquid biopsies in cancer. It will cover what is already in clinical practice, what is on the horizon for liquid biopsies in cancer patient management and the latest new techniques.
This meeting aims to develop our understanding of the potential of liquid biopsies. This includes to support early detection of cancer; as prognostic, pharmacodynamic and predictive biomarkers of treatment efficacy and resistance; and for patient monitoring, including of minimal residual disease for early identification of disease relapse. It will also explore how liquid biopsies can be incorporated in cancer patient management and how implementation of liquid biopsies can change clinical practice.
From basic discoveries to clinical application using minimally invasive clinical bio-specimens. Circulating nucleic acids (ctDNA and RNA), circulating tumor cells, exosomes, patient-derived models (CDX) and CTC cultures.
Translational scientists, biologists, geneticists, clinical chemists, molecular pathologists, oncologists, patient advocates, primary care (GPs), radiologists, clinical and non-clinical trainees, biotech and diagnostic companies, Pharma, bioengineers.
Follow us on twitter for updates @EACRnews and engage with the conference with #LiBi19
Bursary application deadline:
11 March 2019
Abstract submission deadline:
11 March 2019
01 April 2019
Above: the venue, the beautiful city of Bergamo
This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.